MDMA-AT: Application Denied

On August 9, 2024, the FDA handed down a ruling that rejected Lycos Therapeutics' application to approve the treatment of MDMA-assisted therapy for PTSD. The ruling left many of us advocating for psychedelic therapy feeling a little deflated. As the dust has begun to settle on the ruling, there’s a growing realization that this decision might be a blessing in disguise, opening our doors of perception to a more thoughtful and deliberate future for psychedelic-assisted therapy. 

This ruling on MDMA marks a significant milestone, not just in the evolution of this field, but in how we approach it with the care and consideration it deserves. As we navigate this landscape, it’s crucial to keep the promise of psychedelics in motion without going off the proverbial rails. A tempered reset may not only benefit patients but also give us the time to build clinical models that are quality-driven and, for the time being, free from the potential excesses of speculative capital.

 

Moving Forward to a Better Future

The FDA's ruling may have sapped some of the excitement surrounding MDMA, but we now have the opportunity to more firmly refine and establish industry best practices. Let’s appreciate the gift of temperance. Our journey is still unfolding.  In my (mostly) humble opinion, a little more  prep time for research and development will help us lay the groundwork for safer, more effective, and standardized treatment protocols.

 For those of us on the cusp of this transformation, the FDA’s decision offers a valuable window to focus on the essentials: rigorous clinical research, comprehensive staff training, and the development of solid treatment models. These are the roots that will anchor MDMA therapy when it finally blooms into mainstream therapeutic use, ensuring that it does so in a way that maximizes both patient safety and efficacy.

 

Tempering the Tide of Investment

One of the unintended but beneficial consequences of the FDA's ruling is that it will serve to keep investor interest at bay. While investment is crucial for the expansion of psychedelic therapies, premature funding can lead to rushed implementations and, potentially, suboptimal outcomes. By allowing time for the development of robust clinical and operational models, the FDA's decision ensures that when the inevitable wave of investment does arrive, it will be directed towards well-prepared and thoughtfully structured initiatives.

This controlled pace also allows for a more sustainable growth trajectory within the industry. It allows the bravest individuals and organizations to hit the slope with almost no dry powder. Companies can focus on building strong, evidence-based practices rather than being pressured to scale prematurely. This approach will likely result in a more stable and enduring integration of MDMA and potentially other psychedelic therapies into the broader mental health care system.

 

Looking Ahead: COMP360

As our minds expand to consider the future, our thoughts naturally turn to the next potential breakthrough in psychedelic therapy: psilocybin. With Compass Pathways leading the charge, an FDA ruling on pharma-shrooms is anticipated in 2025. This decision could mark another pivotal moment in the ongoing psychedelic renaissance, potentially opening up new therapeutic avenues for treating a variety of mental health conditions.

The anticipation surrounding psilocybin is immense, but just like with MDMA, the importance of a careful and measured approach cannot be overstated. The lessons learned from the MDMA rollout will undoubtedly inform how psilocybin is introduced into clinical settings, helping to ensure that this powerful compound is used responsibly and effectively.

 

Appreciating Alternatives: Ketamine

While MDMA and psilocybin have garnered significant attention, ketamine has quietly established itself as a powerful tool in mental health treatment. Ketamine used for mental health treatment is widespread, with many clinics offering ketamine-assisted therapy for a variety of conditions, including PTSD, anxiety, and chronic pain.

Ketamine works by modulating the brain's glutamate system, which is different from the serotonin pathways that MDMA and psilocybin affect. This gives ketamine a unique advantage in treating patients who may not respond well to traditional antidepressants or who have conditions like suicidal ideation, where rapid relief is crucial. Ketamine’s ability to produce dissociative effects can also help patients gain distance from traumatic memories, making it a potent option for those struggling with deeply ingrained psychological trauma. This adaptability has made it a crucial component of Advaya’s treatment offerings, providing relief for patients who may otherwise have to wait years for MDMA or psilocybin to gain approval.

As the psychedelic space continues to mature, ketamine offers a valuable bridge for those seeking alternative treatments right now. While we remain hopeful for the future of MDMA and psilocybin-assisted therapies, ketamine is already here, providing immediate relief to many in need. At Advaya, we’ve seen firsthand how transformative ketamine can be, and we remain committed to integrating it as part of a comprehensive, patient-centered approach to mental health care.  Reach out today to learn about options to work with Advaya and our partners using ketamine as a treatment.

‍

Fine-Tuning the Psychedelic Future

Providers will continue to plug away and fine-tune our operational dials like deejays working the levels on a mixer. By giving the clinical community more time to establish best practices and operational models, we are setting the stage for a future where psychedelic-assisted therapies are not only widely available but also delivered with the highest standards of care. Here at Advaya, we’re embracing this opportunity to learn, grow, and continue our mission to expand access to psychedelic care. The trip is unfolding and we haven’t peaked yet!

 Also, as a last-minute thought: As we wait for medicines to come online, we can continue to work toward decriminalization and outright legalization as mechanisms to provide access to patients in need. That topic, my friends, would need to be accomplished in another blog post.

‍